Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
$9.99
-$0.29(-2.36%)
At close: 4:00 PM EST
$9.99
-$0.29(-2.36%)
Day’s Range― - ―
52-Week Range$8.87 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)901.50K
Market Cap
$357.86M
Enterprise Value$467.56M
Total Cash (Recent Filing)$81.00M
Total Debt (Recent Filing)$993.00K
Price to Earnings (P/E)219.6
Beta1.49
Next Earnings
Nov 04, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding34,981,255
10 Day Avg. Volume1,296,042
30 Day Avg. Volume901,503
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue6.82
Enterprise Value/Gross Profit7.75
Enterprise Value/Ebitda35.13
Forecast
1Y Price Target
$24.40Price Target Upside144.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe CHOPIN study demonstrated a substantial increase in 1-year Progression Free Survival (PFS), and a statistically significant increase in median PFS.
Future Growth OpportunitiesExpansion opportunities for Hepzato in liver metastases in breast and colorectal cancer are anticipated, suggesting potential growth avenues.
Product AdoptionCHOPIN data should increase Hepzato uptake, anticipate compendia listing.
Bears Say
Adverse EventsThe main challenge to widespread adoption of combination therapy is the high rates of Grade 3+ adverse events, though this is comparable to other safety outcomes.
Financial PerformanceDelcath issued preliminary 3Q25 financial results and lowered revenue guidance for FY2025.
Revenue DeclineUnexpected headwinds impacted HEPZATO sequential growth, with total revenues down 15% QoQ.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $8.87 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $357.86M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Nov 04, 2025 which is in 7 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Aug 06, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.027 by $0.043.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is >-0.01.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 34,981,255 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.07 in its last earnings report, beating expectations of $0.027. Following the earnings report the stock price went up 1.141%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
Delcath Systems Stock Smart Score
Company Description
Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the company's strong revenue growth and positive financial performance, along with strategic expansions and future trial prospects. However, the call also noted challenges in site activations, revenue guidance adjustments, and increased R&D expenses. The participation in the 340B program presents both opportunities and challenges.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$24.40
▲(144.24% Upside)
Technical Analysis
SurModics
―
ClearPoint Neuro
―
Senseonics Holdings
―
Nano-X Imaging
―
Treace Medical Concepts
―
Ownership Overview
31.14% Insiders
6.63% Mutual Funds
23.24% Other Institutional Investors
30.74% Public Companies and Individual Investors
Options Prices
Currently, No data available
---